Closed · HT942526MSRPCTA · CFDA 12.420 · Discretionary
DoW Multiple Sclerosis Clinical Trial Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- August 13, 2026
- Close date
- 3
- Expected awards
The verdict
DoW Multiple Sclerosis Clinical Trial Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 3 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.
- Varies
- award range
- Closed
- application status
- 3
- expected awards
- 12.420
- CFDA program
Recently closed NOFO
This listing closed on August 13, 2026. CFDA 12.420 may re-announce under a new opportunity number. Historical award band was Varies by applicant.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed August 13, 2026
Est. Total Funding
$4,000,000
Expected Awards
3
Instrument
Grant
Description
Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies.Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level:• Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial are required.• Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the proposed clinical trial in MS populations are required.For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted.
Catch-all / unrestricted eligibility mark · HT942526MSRPCTA
Grants.gov marks DoW Multiple Sclerosis Clinical Trial Award with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).
- Code 99
- Unrestricted / see official listing
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
What to do next
DoW Multiple Sclerosis Clinical Trial Award is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- Compare award ranges across federal categories before you pick a single CFDA. All categories
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |